Overview

Study of CM313(SC) Injection in Systemic Lupus Erythematosus(SLE)

Status:
NOT_YET_RECRUITING
Trial end date:
2027-02-01
Target enrollment:
Participant gender:
Summary
To evaluate the efficacy and safety of CM313(SC) injection in systemic lupus erythematosus(SLE)
Phase:
PHASE2
Details
Lead Sponsor:
Keymed Biosciences Co.Ltd